Abstract
Purpose
To study the evolution and optimal management of metastatic bone disease (mBD) in patients with neuroendocrine neoplasms (NENs).
Methods
Seventy-four patients were recruited from four NEN centers in this observational multicenter study.
Results
Pancreas and small bowel were the most common primaries (30 and 27%, respectively). Almost all gastrointestinal (GI)-NENs were grades 1 and 2, whereas bronchopulmonary-thymic were atypical carcinoids. Thirty-two (43%) patients had synchronous metastatic bone disease (mBD) and three patients reported bone-specific symptoms; metachronous mBD developed at a median of 35 (range: 4–395) months. Thirty-six (86%) of patients with metachronous mBD had stage IV disease at diagnosis. Somatostatin receptor functional imaging and computed tomography were the modalities mostly used for mBD identification. Fifty-two patients received assessable bone-related therapy (bisphosphonates, denosumab, local radiotherapy, and radionuclide treatment). Improvement in mBD was seen in 5, stable disease in 22, and deterioration in 25 patients. The presence of synchronous mBD and the negative outcome of bone-related therapy negatively affected overall survival (OS). In the multivariate analysis, the stronger predictor of OS was the outcome of bone-related therapy (HR: 4.753; 95% CI: 1.589–14.213). Bisphosphonates therapy was the mostly used bone-specific treatment but its monthly administration did not affect OS. At last follow-up, 39 patients were alive with OS 50 (14–463) months.
Conclusions
Early investigation for mBD offers a prognostic marker of patients with NENs, since synchronous mBD has a negative impact on survival. The outcome of bone-related therapy affects OS but the monthly administration of bisphosphonates did not show a benefit over less intense schemes.
Similar content being viewed by others
References
W.G. Meijer, E. van der Veer, P.L. Jager, E.J. van der Jagt, B.A. Piers, I.P. Kema, E.G. de Vries, P.H. Willemse, Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism. J. Nucl. Med. 44, 184–191 (2003)
R. Hlatky, D. Suki, R. Sawaya, Carcinoid metastasis to the brain. Cancer 101, 2605–2613 (2004)
C. Lombard-Bohas, E. Mitry, D. O’Toole, C. Louvet, D. Pillon, G. Cadiot, F. Borson-Chazot, T. Aparicio, M. Ducreux, T. Lecomte, P.L. Etienne, W. Cacheux, J.L. Legoux, J.F. Seitz, P. Ruszniewski, J.A. Chayvialle, P. Rougier, FFCD-ANGH-GERCOR, Thirteen-month registration of patients with gastroenteropancreatic endocrine tumours in France. Neuroendocrinology 89, 217–222 (2009).
J. Keiser, E.K. Nakakura, L. Imhoff, M.A. Mayorga, S. Bobiak, A.P. Venook, E.K. Bergsland, Incidence and natural history of bone metastases in neuroendocrine tumors [Abstract]. J. Clin. Oncol. 30(Suppl 4), 340 (2012)
E.T. Janson, L. Holmberg, M. Stridsberg, B. Eriksson, E. Theodorsson, E. Wilander, K. Oberg, Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann. Oncol. 8, 685–690 (1997)
E.M. Ross, W.C. Roberts, The carcinoid syndrome: comparison of 21 necropsy subjects with carcinoid heart disease to 15 necropsy subjects without carcinoid heart disease. Am. J. Med. 79, 339–354 (1985)
J.M. Zuetenhorst, C.A. Hoefnageli, H. Boot, R.A. Valdés Olmos, B.G. Taal, Evaluation of (111)In-pentetreotide, (131)I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease. Nucl. Med. Commun. 23, 735–741 (2002)
J.M. Zuetenhorst, B.G. Taal, Metastatic carcinoid tumors: a clinical review. Oncologist 10, 123–131 (2005)
F. Macedo, K. Ladeira, F. Pinho, N. Saraiva, N. Bonito, L. Pinto, F. Goncalves, Bone metastases: an overview. Oncol. Rev. 11, 321 (2017)
M. Gnant, P. Clézardin, Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. Cancer Treat. Rev. 38, 407–415 (2012)
L.S. Rosen, D. Gordon, N.S. Tchekmedyian, R. Yanagihara, V. Hirsh, M. Krzakowski, M. Pawlicki, P. De Souza, M. Zheng, G. Urbanowitz, D. Reitsma, J. Seaman, Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 100, 2613–2621 (2004)
S. Sousa, P. Clézardin, Bone-targeted therapies in cancer-induced bone disease. Calcif. Tissue Int. 102, 227–250 (2018)
K. Alexandraki, A. Angelousi, G. Boutzios, G. Kyriakopoulos, D. Rontogianni, G. Kaltsas, Management of neuroendocrine tumors of unknown primary. Rev. Endocr. Metab. Disord. 18, 423–431 (2017)
K. Van Loon, L. Zhang, J. Keiser, C. Carrasco, K. Glass, M.T. Ramirez, S. Bobiak, E.K. Nakakura, A.P. Venook, M.H. Shah, E.K. Bergsland, Bone metastases and skeletal-related events from neuroendocrine tumors. Endocr. Connect. 4, 9–17 (2015)
M. Scharf, V. Petry, H. Daniel, A. Rinke, T.M. Gress, Bone metastases in patients with neuroendocrine neoplasm: frequency and clinical, therapeutic, and prognostic relevance. Neuroendocrinology 106, 30–37 (2018)
D.H. Nguyen, P.T. Truong, C.V. Walter, E. Hayashi, J.L. Christie, C. Alexander, Limited M1 disease: a significant prognostic factor for stage IV breast cancer. Ann. Surg. Oncol. 19, 3028–3034 (2012)
P. Soyer, A. Roche, D. Elias, M. Levesque, Hepatic metastases from colorectal cancer: influence of hepatic volumetric analysis on surgical decision making. Radiology 184, 695–697 (1992)
A. Perren, A. Couvelard, J.Y. Scoazec, F. Costa, I. Borbath, G. Delle Fave, V. Gorbounova, D. Gross, A. Grossman, R.T. Jense, M. Kulke, K. Oeberg, G. Rindi, H. Sorbye, S. Welin; Antibes Consensus Conference participants, ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and Prognostic Stratification. Neuroendocrinology 105, 196–200 (2017)
F. Panzuto, S. Nasoni, M. Falconi, V.D. Corleto, G. Capurso, S. Cassetta, M. Di Fonzo, V. Tornatore, M. Milione, S. Angeletti, M.S. Cattaruzza, V. Ziparo, C. Bordi, P. Pederzoli, G. Delle Fave, Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr. Relat. Cancer 12, 1083–1092 (2005)
B. Kos-Kudła, D. O’Toole, M. Falconi, D. Gross, G. Klöppel, A. Sundin, J. Ramage, K. Oberg, B. Wiedenmann, P. Komminoth, E. Van Custem, M. Mallath, M. Papotti, M. Caplin; Palma de Mallorca Consensus Conference Participants, ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors. Neuroendocrinology 91, 341–350 (2010)
G. Kaltsas, A. Rockall, D. Papadogias, R. Reznek, A.B. Grossman., Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur. J. Endocrinol. 151, 15–27 (2004)
U. Knigge, J. Capdevila, D.K. Bartsch, E. Baudin, J. Falkerby, R. Kianmanesh, B. Kos-Kudla, B. Niederle, E. Nieveen van Dijkum, D. O’Toole, A. Pascher, N. Reed, A. Sundin, M.P. Vullierme; Antibes Consensus Conference Participants; Antibes Consensus Conference participants, ENETS Consensus Recommendations for the Standards of Care in Neuroendocrine Neoplasms: follow-up and documentation. Neuroendocrinology 105, 310–319 (2017)
D. Putzer, M. Gabriel, B. Henninger, D. Kendler, C. Uprimny, G. Dobrozemsky, C. Decristoforo, R.J. Bale, W. Jaschke, I.J. Virgolini, Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J. Nucl. Med. 50, 1214–1221 (2009)
H.J. Hansmann, C. Wunsch, B. Schneider, M. Brado, M. Flesch, G.M. Richter, G.W. Kauffmann, Radiologic diagnosis of bone metastases. Orthopade 27, 224–230 (1998)
J. Kavecansky, L. Wei, L. Caronia, M.T. Ramirez, M. Bloomston, M.H. Shah, Bone metastases in well-to-moderately differentiated neuroendocrine tumors: a single institutional review from the Ohio State University Medical Center. Pancreas 44, 198–203 (2015)
F. Gibril, J.L. Doppman, J.C. Reynolds, C.C. Chen, V.E. Sutliff, F. Yu, J. Serrano, D.J. Venzon, R.T. Jensen, Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and magnetic resonance image in their detection, frequency, location, and effect of their detection on management. J. Clin. Oncol. 16, 1040–1053 (1998)
R. Lebtahi, G. Cadiot, N. Delahaye, R. Genin, D. Daou, M.C. Peker, D. Chosidow, M. Faraggi, M. Mignon, D. Le Guludec, Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy. J. Nucl. Med. 40, 1602–1608 (1999)
M. Raderer, A. Kurtaran, M. Leimer, P. Angelberger, B. Niederle, H. Vierhapper, F. Vorbeck, M.H. Hejna, W. Scheithauer, J. Pidlich, I. Virgolini, Value of peptide receptor scintigraphy using (123)I-vasoactive intestinal peptide and (111)In-DTPA-D-Phe1-octreotide in 194 carcinoid patients: Vienna University Experience, 1993 to 1998. J. Clin. Oncol. 18, 1331–1336 (2000)
D.J. Kwekkeboom, J.J. Teunissen, W.H. Bakker, P.P. Kooij, W.W. de Herder, R.A. Feelders, C.H. van Eijck, J.P. Esser, B.L. Kam, E.P. Krenning., Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J. Clin. Oncol. 23, 2754–2762 (2005)
A. Sabet, F. Khalaf, T. Haslerud, A. Al-Zreiqat, A. Sabet, B. Simon, T.D. Pöppel, H.J. Biersack, S. Ezziddin, Bone metastases in GEP-NET: response and long-term outcome after PRRT from a follow-up analysis. Am. J. Nucl. Med. Mol. Imaging 3, 437–445 (2013)
S. Ezziddin, A. Sabet, F. Heinemann, C.J. Yong-Hing, H. Ahmadzadehfar, S. Guhlke, T. Höller, W. Willinek, C. Boy, H.J. Biersack, Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate. J. Nucl. Med. 52, 1197–1203 (2011)
M. Gnant, J. Baselga, H.S. Rugo, S. Noguchi, H.A. Burris, M. Piccart, G.N. Hortobagyi, J. Eakle, H. Mukai, H. Iwata, M. Geberth, L.L. Hart, P. Hadji, M. El-Hashimy, S. Rao, T. Taran, T. Sahmoud, D. Lebwohl, M. Campone, K.I. Pritchard, Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. J. Natl. Cancer Inst. 105, 654–663 (2013)
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Formal consent was given by all participants.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
These authors should be considered as senior authors: Gregory Kaltsas, Martin O. Weickert
Rights and permissions
About this article
Cite this article
Alexandraki, K.I., Pizanias, M., Uri, I. et al. The prognosis and management of neuroendocrine neoplasms-related metastatic bone disease: lessons from clinical practice. Endocrine 64, 690–701 (2019). https://doi.org/10.1007/s12020-019-01838-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-019-01838-8